Please ensure Javascript is enabled for purposes of website accessibility

Roche Spends $451 Million to Acquire Inflazome's NLRP3 Program

By Todd Campbell – Sep 21, 2020 at 2:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The deal will provide the pharma giant with a unique new platform for tackling autoimmune diseases.

In a forward-looking move that could provide it with new drugs to fight a variety of autoimmune disorders, healthcare giant Roche (RHHBY -1.10%) is acquiring Ireland-based Inflazome for 380 million euros, about $451 million at the current exchange rate.

The acquisition will bring with it Inflazome's oral NLRP3 program, including two small-molecule inflammasome inhibitors in early-stage clinical trials. The NLRP3 gene provides the body with instructions to make cryopyrin, a protein that spots molecular danger signals and prompts an immune system reaction to infections and tissue damage.

A man in a suit speaks through a megaphone.


Over-activation of the immune system can contribute to various disorders, including Parkinson's and Alzheimer's disease, as well as asthma, arthritis, and chronic kidney disease. Phase 1 clinical trials for two Inflazome drugs, inzomelid and somalix, are complete, and phase 2 studies are set to begin this year. 

Initially, inzomelid is being evaluated in three rare disorders caused by NLRP3 mutations: familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease. However, because it can pass the blood-brain barrier, Roche may evaluate it in larger neurological indications, including Alzheimer's disease and Parkinson's disease.

Somalix is designed to avoid interacting with the central nervous system, so it's being evaluated in non-neurological indications such as gout, cardiovascular disease, and arthritis.

If Inflazome's pipeline succeeds, then its shareholders will be eligible to receive milestone payments over and above the 380 million euro purchase price.

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Roche Holding AG Stock Quote
Roche Holding AG
$39.60 (-1.10%) $0.44

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.